Nykode Therapeutics is at the forefront of innovative vaccine development, leveraging its proprietary Vaccibody platform to create targeted immunotherapies for cancer, autoimmune diseases, and infectious diseases. The Vaccibody technology is designed to induce robust and long-lasting immune responses by delivering antigens specifically to antigen-presenting cells (APCs). This modular approach allows for the customization of the targeting unit, enabling the vaccines to elicit specific immune responses tailored to the disease at hand. Notably, the platform has shown promise in treating HPV-driven cancers through its lead product candidate, VB10.16, which targets malignancies associated with the Human Papillomavirus (HPV) and has demonstrated early signs of clinical efficacy in various trials.

In addition to its cancer-focused initiatives, Nykode is pioneering the development of individualized cancer vaccines, such as VB10.NEO, which target unique neoantigens arising from somatic mutations in tumors. This personalized approach aims to harness the patient's immune system to recognize and attack their specific cancer cells. Furthermore, Nykode is exploring innovative strategies for autoimmune diseases through its "inverse vaccine" concept, which aims to restore immune tolerance by targeting autoreactive T cells while preserving overall immune competence. This multifaceted platform not only enhances the potential for effective treatments across various therapeutic areas but also positions Nykode Therapeutics as a leader in the evolving landscape of precision medicine.

Norway

We are a leading technology platform that unlocks unlimited possibilities for the future of medicine through our intelligent modular design and tailored hyper targeting.

Cancer

Infectious Diseases

Kidney Diseases

Lung Diseases

Urogenital Diseases

Nykode Therapeutics

Cervical cancer

Human Papillomavirus

VBIO.16

Biologics

Vaccines

Head and neck squamous cell carcinoma

Bladder cancer

Head and neck cancer

Lung disease

Melanoma

Renal disease

VBIO.NEO

Regeneron program 1/2/3

Solid tumor/s

Infectious disease

Regeneron program 4/ 5

Europe - West

Gene Therapy

Therapeutic

Nykode Therapeutics

Company Details